397 related articles for article (PubMed ID: 28399672)
1. Targeting adenosine in cancer immunotherapy: a review of recent progress.
Whiteside TL
Expert Rev Anticancer Ther; 2017 Jun; 17(6):527-535. PubMed ID: 28399672
[TBL] [Abstract][Full Text] [Related]
2. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.
Azambuja JH; Ludwig N; Braganhol E; Whiteside TL
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739402
[TBL] [Abstract][Full Text] [Related]
4. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
5. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
6. Immunoregulatory activity of adenosine and its role in human cancer progression.
Muller-Haegele S; Muller L; Whiteside TL
Expert Rev Clin Immunol; 2014 Jul; 10(7):897-914. PubMed ID: 24871693
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive activities of adenosine in cancer.
Allard B; Beavis PA; Darcy PK; Stagg J
Curr Opin Pharmacol; 2016 Aug; 29():7-16. PubMed ID: 27209048
[TBL] [Abstract][Full Text] [Related]
8. Targeting the adenosine pathway for cancer immunotherapy.
Hammami A; Allard D; Allard B; Stagg J
Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
[TBL] [Abstract][Full Text] [Related]
9. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
10. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
11. Adenosine Metabolism: Emerging Concepts for Cancer Therapy.
Boison D; Yegutkin GG
Cancer Cell; 2019 Dec; 36(6):582-596. PubMed ID: 31821783
[TBL] [Abstract][Full Text] [Related]
12. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
Sek K; Mølck C; Stewart GD; Kats L; Darcy PK; Beavis PA
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513816
[TBL] [Abstract][Full Text] [Related]
13. Role of m
Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?
Whiteside TL
Cancer Immunol Immunother; 2014 Jan; 63(1):67-72. PubMed ID: 24213679
[TBL] [Abstract][Full Text] [Related]
15. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity.
Silva-Vilches C; Ring S; Mahnke K
Front Immunol; 2018; 9():2581. PubMed ID: 30473700
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
17. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
De Jaeghere EA; Denys HG; De Wever O
Trends Cancer; 2019 Nov; 5(11):704-723. PubMed ID: 31735289
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.
Hussain M; Shah Z; Abbas N; Javeed A; Mukhtar MM; Zhang J
Med Hypotheses; 2016 Jan; 86():56-9. PubMed ID: 26804598
[TBL] [Abstract][Full Text] [Related]
19. Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.
Zhang M; Dai X; Xiang Y; Xie L; Sun M; Shi J
Eur J Med Chem; 2023 Oct; 258():115546. PubMed ID: 37302340
[TBL] [Abstract][Full Text] [Related]
20. The immune response in cancer: from immunology to pathology to immunotherapy.
Giraldo NA; Becht E; Vano Y; Sautès-Fridman C; Fridman WH
Virchows Arch; 2015 Aug; 467(2):127-35. PubMed ID: 26077464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
